• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Daniel A. Haber, MD, PhD


  • Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR.A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.Clin Cancer Res. 2013 Apr 3.
  • Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner M.Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.Sci Transl Med. 2013 Apr 3;5(179):179ra47.
  • Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran S.Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.Science. 2013 Feb 1;339(6119):580-4.
  • Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, McDermott U, Garnett MJ.Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61.
  • Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DE.An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.Nature. 2012 Nov 15;491(7424):449-53.
  • Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA.Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.Cancer Discovery. 2012 Nov;2(11):995-1003.
  • Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DA.RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis.Nature. 2012 Jul 26;487(7408):510-3.
  • Haber DA, Gray NS, Baselga J.The evolving war on cancer.Cell. 2011 Apr 1;145(1):19-24.
  • Yu M, Stott S, Toner M, Maheswaran S, Haber DA.Circulating tumor cells: approaches to isolation and characterization.J Cell Biol. 2011 Feb 7;192(3):373-82.
  • Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DA.Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers.Science. 2011 Feb 4;331(6017):593-6.
  • Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DA.Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers.Science. Published Online January 13 2011 ;Science DOI: 10.1126/science.1200801 .
  • Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, Yu M, Ng LW, Scherber CM, Schott BJ, Ramaswamy S, Irimia D, Root DE, Haber DA.A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration.Genes Dev. 2010 Dec 1;24(23):2654-65.
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, J√§nne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
  • Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner M.Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18392-7.
  • Ozsolak F, Ting DT, Wittner BS, Brannigan BW, Paul S, Bardeesy N, Ramaswamy S, Milos PM, Haber DA.Amplification-free digital gene expression profiling from minute cell quantities.Nat Methods. 2010 Aug;7(8):619-21.
  • Wells J, Rivera MN, Kim WJ, Starbuck K, Haber DA.The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes.Mol Cancer Res. 2010 Jul;8(7):975-85.
  • Aiden AP, Rivera MN, Rheinbay E, Ku M, Coffman EJ, Truong TT, Vargas SO, Lander ES, Haber DA, Bernstein BE.Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network.Cell Stem Cell. 2010 Jun 4;6(6):591-602.
  • Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJ.Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.EMBO Mol Med. 2010 May;2(5):146-58.
  • Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S.Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.Sci Transl Med. 2010 Mar 31;2(25):25ra23.
  • Sharma SV, Haber DA, Settleman J.Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.Nat Rev Cancer. 2010 Apr;10(4):241-53. Review.
  • Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DA.A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.Cancer Res. 2010 Mar 15;70(6):2158-64.
  • Maheswaran S, Haber DA.Circulating tumor cells: a window into cancer biology and metastasis.Curr Opin Genet Dev. 2010 Feb;20(1):96-9. Review.
  • Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DA.YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway.Nat Cell Biol. 2009 Dec;11(12):1444-50.
  • Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, Bell DW.Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin.Mol Cancer Res. 2009 Sep;7(9):1510-6.
  • Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ, Brachtel E, Ramaswamy S, Maheswaran S, Haber DA.A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.Genes Dev. 2009 Aug 1;23(15):1737-42.
  • Rivera MN,Kim WJ,Wells J,Stone A,Burger A,Coffman EJ,Zhang J,Haber DA.The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity.Proc Natl Acad Sci U S A. 2009 May 19;106(20):8338-43.
  • McDermott U,Ames RY,Iafrate AJ,Maheswaran S,Stubbs H,Greninger P,McCutcheon K,Milano R,Tam A,Lee DY,Lucien L,Brannigan BW,Ulkus LE,Ma XJ,Erlander MG,Haber DA,Sharma SV,Settleman J.Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.Cancer Res. 2009 May 1;69(9):3937-46.
  • Sequist LV,Nagrath S,Toner M,Haber DA,Lynch TJ.The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.J Thorac Oncol. 2009 Mar;4(3):281-3.
  • Chin TM,Quinlan MP,Singh A,Sequist LV,Lynch TJ,Haber DA,Sharma SV,Settleman J.Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.Clin Cancer Res. 2008 Nov 1;14(21):6867-76.
  • Rothenberg SM,Engelman JA,Le S,Riese DJ 2nd,Haber DA,Settleman J.Modeling oncogene addiction using RNA interference.Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12480-4.
  • Maheswaran S,Sequist LV,Nagrath S,Ulkus L,Brannigan B,Collura CV,Inserra E,Diederichs S,Iafrate AJ,Bell DW,Digumarthy S,Muzikansky A,Irimia D,Settleman J,Tompkins RG,Lynch TJ,Toner M,Haber DA.Detection of mutations in EGFR in circulating lung-cancer cells.N Engl J Med. 2008 Jul 24;359(4):366-77.
  • Bell DW,Brannigan BW,Matsuo K,Finkelstein DM,Sordella R,Settleman J,Mitsudomi T,Haber DA.Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.Clin Cancer Res. 2008 Jul 1;14(13):4079-84.
  • Diederichs S,Jung S,Rothenberg SM,Smolen GA,Mlody BG,Haber DA.Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites.Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9284-9.
  • Montagut C,Sharma SV,Shioda T,McDermott U,Ulman M,Ulkus LE,Dias-Santagata D,Stubbs H,Lee DY,Singh A,Drew L,Haber DA,Settleman J.Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.Cancer Res. 2008 Jun 15;68(12):4853-61.
  • Li H,Smolen GA,Beers LF,Xia L,Gerald W,Wang J,Haber DA,Lee SB.Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor.PLoS ONE. 2008;3(6):e2353.
  • Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR Mutations.J Clin Oncol. 2008 May 20;26(15):2442-9.
  • Wittner BS,Sgroi DC,Ryan PD,Bruinsma TJ,Glas AM,Male A,Dahiya S,Habin K,Bernards R,Haber DA,Van't Veer LJ,Ramaswamy S.Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.Clin Cancer Res. 2008 May 15;14(10):2988-93.
  • McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman J.Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.Cancer Res. 2008 May 1;68(9):3389-95.
  • Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DA.The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.Mol Cancer Ther. 2008 Apr;7(4):874-9.
  • Zhang J, Smolen GA, Haber DA.Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway.Cancer Res. 2008 Apr 15;68(8):2789-94.
  • Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DA.Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.Blood. 2008 May 1;111(9):4716-22.
  • Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M.Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature. 2007 Dec 20;450(7173):1235-9.
  • Diederichs S, Haber DA.Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression.Cell. 2007 Dec 14;131(6):1097-108.
  • McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
  • Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML.Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.Int J Cancer. 2007 Dec 15;121(12):2661-7.
  • Smolen GA, Schott BJ, Stewart RA, Diederichs S, Muir B, Provencher HL, Look AT, Sgroi DC, Peterson RT, Haber DA.A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors.Genes Dev. 2007 Sep 1;21(17):2131-6.
  • Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DA.Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.Cancer Res. 2007 Aug 1;67(15):7319-26.
  • Han M, Rivera MN, Batten JM, Haber DA, Cin PD, Iafrate AJ.Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene.Genes Chromosomes Cancer. 2007 Oct;46(10):909-13.
  • Haber DA, Settleman J.Cancer: drivers and passengers.Nature. 2007 Mar 8;446(7132):145-6.
  • Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman J.Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.Cancer Res. 2007 Mar 1;67(5):2325-30.
  • Sharma SV, Bell DW, Settleman J, Haber DA.Epidermal growth factor receptor mutations in lung cancer.Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.
  • Sequist LV, Bell DW, Lynch TJ, Haber DA.Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.J Clin Oncol. 2007 Feb 10;25(5):587-95. Review.
  • Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, Pylkas K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R.A recurrent mutation in PALB2 in Finnish cancer families.Nature. 2007 Mar 15;446(7133):316-9.
  • Sequist LV, Joshi VA, Jšnne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ.Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.Oncologist. 2007 Jan;12(1):90-8.
  • Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DA.An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.Science. 2007 Feb 2;315(5812):642-5.
  • Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman J.A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.Cancer Cell. 2006 Nov;10(5):425-35.
  • Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DA.Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12405-10.
  • Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman J.Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.Cold Spring Harb Symp Quant Biol. 2005;70:419-26. Review.
  • Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jšnne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CS.Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.Clin Cancer Res. 2006 Jul 15;12(14):4365s-71s.
  • Sequist LV, Joshi VA, Jšnne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ.Epidermal growth factor receptor mutation testing in the care of lung cancer patients.Clin Cancer Res. 2006 Jul 15;12(14):4403s-8s. Review.
  • Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DW.Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7.
  • Sharma SV, Fischbach MA, Haber DA, Settleman J."Oncogenic Shock": Explaining Oncogene Addiction through Differential Signal Attenuation.Clin Cancer Res. 2006 Jul 15;12(14):4392s-5s. Review.
  • Bell DW, Haber DA.A blood-based test for epidermal growth factor receptor mutations in lung cancer.Clin Cancer Res. 2006 Jul 1;12(13):3875-7. Review.
  • Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jšnne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res. 2006 Jul 1;12(13):3908-14.
  • Diederichs S, Haber DA.Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing.Cancer Res. 2006 Jun 15;66(12):6097-104.
  • Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DA.Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.Cancer Res. 2006 Apr 1;66(7):3452-5.
  • Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DA.Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.Cancer Res. 2006 Feb 15;66(4):1923-8.
  • Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA.Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2316-21.
  • Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DA.Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.Nat Genet. 2005 Dec;37(12):1315-6.
  • Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA.Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.J Clin Oncol. 2005 Nov 1;23(31):8081-92.
  • Sequist LV, Haber DA, Lynch TJ.Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.Clin Cancer Res. 2005 Aug 15;11(16):5668-70.
  • Lorenzen JA, Bonacci BB, Palmer RE, Wells C, Zhang J, Haber DA, Goldstein AM, Mayer AN.Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium.Gene Expr Patterns. 2005 Dec;6(1):45-56.
  • Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA.Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Proc Natl Acad Sci U S A. 2005 May 24;102(21):7665-70.
  • Song YH, Mirey G, Betson M, Haber DA, Settleman J.The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development.Curr Biol. 2004 Aug 10;14(15):1354-9.
  • Sordella R, Bell DW, Haber DA, Settleman J.Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Science. 2004 Aug 20;305(5687):1163-7.
  • Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC.A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.Cancer Cell. 2004 Jun;5(6):607-16.
  • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med. 2004 May 20;350(21):2129-39.
  • Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I, Dombkowski D, Olson DP, Hancock J, Choi PS, Haber DA, Luster AD, Scadden DT.P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells.Genes Dev. 2003 Jul 1;17(13):1592-604.
  • Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA.DOCK4, a GTPase activator, is disrupted during tumorigenesis.Cell. 2003 Mar 7;112(5):673-84.
  • Palmer RE, Lee SB, Wong JC, Reynolds PA, Zhang H, Truong V, Oliner JD, Gerald WL, Haber DA.Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis.Cancer Cell. 2002 Dec;2(6):497-505.
  • Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DA.REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.Mol Cell. 2002 Nov;10(5):995-1005.
  • Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA, Hariharan IK.salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines.Cell. 2002 Aug 23;110(4):467-78.
  • Bell DW, Erban J, Sgroi DC, Haber DA.Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.Cancer Res. 2002 May 15;62(10):2741-3.
  • Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA.Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.Cancer Res. 2001 Nov 15;61(22):8062-7.
  • Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DA.WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.Curr Biol. 2001 Nov 13;11(22):1805-9.
  • Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK.Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines.Nature. 2001 Sep 20;413(6853):311-6.
  • Ellisen LW, Palmer RE, Maki RG, Truong VB, Tamayo P, Oliner JD, Haber DA.Cascades of transcriptional induction during human lymphocyte activation.Eur J Cell Biol. 2001 May;80(5):321-8.
  • Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM.BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.Cell. 2001 Apr 6;105(1):149-60.
  • Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DA.The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells.EMBO J. 2001 Apr 17;20(8):1897-909.
  • Wang W, Lee SB, Palmer R, Ellisen LW, Haber DA.A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1.J Biol Chem. 2001 May 18;276(20):16810-6.
  • Lee SB, Haber DA.Wilms tumor and the WT1 gene.Exp Cell Res. 2001 Mar 10;264(1):74-99.
  • Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, Haber DA, Nichols KE.Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene.Blood. 2001 Feb 15;97(4):1131-3.
  • Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak K.Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.Cancer Res. 2000 Dec 15;60(24):6859-63.
  • Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, Finkelstein D, Forcione D, Pillai S.Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11451-4.
  • Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA.Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.Science. 1999 Dec 24;286(5449):2528-31.
  • Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA.Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor.Genes Chromosomes Cancer. 2000 Feb;27(2):124-9.
  • Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L.Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease.J Clin Oncol. 1999 Apr;17(4):1259.
  • Okano M, Bell DW, Haber DA, Li E.DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.Cell. 1999 Oct 29;99(3):247-57.
  • Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DA.The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.Cell. 1999 Sep 3;98(5):663-73.
  • Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DA.Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.Cell. 1999 May 28;97(5):575-86.
  • Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, Bean J, Ezzell R, Garvin AJ, McCluskey RT, DeCaprio JA, Haber DA.Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.Genes Dev. 1998 Apr 15;12(8):1108-20.
  • Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA.Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase.Oncogene. 1998 Mar 5;16(9):1217-22.
  • Ellisen LW, Haber DA.Hereditary breast cancer.Annu Rev Med. 1998;49:425-36.
  • Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA.hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.Cell. 1997 Aug 22;90(4):785-95.
  • FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA.Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.N Engl J Med. 1996 Jan 18;334(3):143-9.
  • Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DA.The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.Genes Dev. 1995 Sep 1;9(17):2143-56.
  • Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DE.An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor.Cell. 1990 Jun 29;61(7):1257-69.
  • Haber DA, Schimke RT.Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes.Cell. 1981 Nov;26(3 Pt 1):355-62.